Russian drugmaker Axelpharm has managed to lift the ban on the launch of osimertinib - a drug, which is used in the treatment ...

Research services company IQVIA has unveiled new AI agents built using NVIDIA technology that are designed to enhance ...

Kite, unit today presented the latest results that demonstrate a 79% overall response rate (ORR) and 74% overall survival (OS ...

South Korea’s biosimilar drug developer Samsung Bioepis today presented the long-term safety data of Epysqli (eculizumab; ...

US biotech Novavax (Nasdaq: NVAX) has reported that its experimental combination COVID-19 and influenza vaccine generated ...

Biogen has highlighted the growing role of felzartamab in its pipeline during a virtual investor seminar, spotlighting three ...

The US Food and Drug Administration (FDA) yesterday approved Nuvation Bio’s (NYSE: NUVB) Ibtrozi (taletrectinib), a kinase ...

French biotech Enterome has secured $19 million in private funding to accelerate development of its OncoMimics immunotherapy ...

California-based clinical-stage biotech Juvena Therapeutics has entered a global licensing and multi-target research ...

South Korea’s LigaChem Biosciences has signed two antibody licensing agreements with US biotech NovaRock Biotherapeutics, reports Korea Biomedical Review.

Sino-American oncology company BeOne Medicines (Nasdaq: ONC) is presenting new clinical data from cornerstone hematology assets at the European Hematology Association (EHA) Congress.

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced new data from the pivotal AUGMENT-101 trial of Revuforj ...